Combined Medical Treatment Of Chronic Pancreatitis

Open access


The aim of the study was to determine the most effective medical treatment of patients with chronic pancreatitis, by using either pancreatin alone or in combination with proton pump inhibitor (PPI) or PPI and non-steroidal anti-inflammatory drug (NSAID). Patients with chronic pancreatitis, who did not require a surgical treatment, received medical treatment for a one–month period: 20 patients received pancreatin monotherapy; 48 patients were given a combination of pancreatin and PPI; 38 patients were treated with a combination of pancreatin, PPI and NSAID (PNP therapy group). In comparison with other groups, patients in the PNP therapy group showed improvement in body mass index, abdominal pain, bowel movements, chronic pancreatitis severity, as well as their quality of life assessment (p < 0.05). The combination of pancreatin, PPI and NSAID was the most effective among those applied in chronic pancreatitis patient treatment. A one–month long course of this therapy was safe and did not cause any significant adverse effects. The combination of pancreatin, PPI and NSAID for treatment of chronic pancreatitis can be recommended, as it is based on pathogenesis of the disease, effective, safe and economically advantageous.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Anonymous (2001). Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws regulations and administrative provisions of the Member States relating to the implementation of Good Clinical Practice in the conduct of clinical trials on medicinal products for human use. OJ EC L121 34–41. (accessed 12 September 2014).

  • Anonymous (1964). WMA Declaration of Helsinki—Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18th WMA General Assembly Helsinki Finland June 1964 and amended by the: 29th WMA General Assembly Tokyo Japan October 1975; 35th WMA General Assembly Venice Italy October 1983; 41st WMA General Assembly Hong Kong September 1989; 64th WMA General Assembly Fortaleza Brazil October 2013. (accessed 12 September 2014).

  • Bai H. Chen X. Zhang L. Dou X. (2012). The effect of sulindac a non-steroidal anti-inflammatory drug attenuates inflammation and fibrosis in a mouse model of chronic pancreatitis. BMC Gastroenterol.24 (12) 115.

  • Brown A. Hughes M. Tenner S. Banks P. (1997). Does pancreatic enzyme supplementation reduce pain in patients with chronic pancreatitis: A meta-analysis. Amer. J. Gastroenterol. 92 (11) 2032–2035.

  • Capurso G. Cocomello L. Benedetto U. Cammà C. Delle Fave G.. (2012). Meta-analysis: The placebo rate of abdominal pain remission in clinical trials of chronic pancreatitis. Pancreas41 (7) 1125–1131.

  • Drummey G. Benson J. Jones C. (1961). Microscopical examination of the stool for steatorrhea. New Engl. J. Med.264 85–87.

  • Frulloni L. Falconi M. Gabbrielli A. et al. (2010). Italian consensus guidelines for chronic pancreatitis. Dig. Liver. Dis. 42 (6) S381–S406.

  • Gigante A. Tagarro I. (2012). Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: A focus on ketoprofen/omeprazole. Clin. Drug Investig.32 (4) 221–233.

  • Grady T. Liang P. Ernst S. Logsdon C. (1997). Chemokine gene expression in rat pancreatic acinar cells is an early event associated with acute pancreatitis. Gastroenterology 113 1966–1975.

  • Halgreen H. Pedersen N. Worning H. (1986). Symptomatic effect of pancreatic enzyme therapy in patients with chronic pancreatitis. Scand. J. Gastroenterol.21 (1) 104–8.

  • Isaksson G. Ihse I. (1983). Pain reduction by an oral pancreatic enzyme preparation in chronic pancreatitis. Dig. Dis. Sci.28 (2) 97–102.

  • Jonasson C. Hatlebakk J. Lundell L. Kouri J. P. Andersen M. Granath F. (2013). Association between adherence to concomitant proton pump inhibitor therapy in current NSAID users and upper gastrointestinal complications. Eur. J. Gastroenterol. Hepatol. 25 (5) 531–538.

  • Larvin M. McMahon M. Thomas W. Puntis M. C. A. (1991). Creon (enteric coated pancreatin microspheres) for the treatment of pain in chronic pancreatitis: A double-blind randomized placebo-controlled crossover study. Gastroenterology100 A283.

  • Lin Y. Tamakoshi A. Matsuno S. Takeda K. Hayakawa T. Kitagawa M. Naruse S. Kawamura T. Wakai K. Aoki R. Kojima M. Ohno Y. (2000). Nationwide epidemiological survey of chronic pancreatitis in Japan. J. Gastroenterol. 35 (2) 136–141.

  • de-Madaria E. Abad-González A. Aparicio J. Aparisi L. Boadas J. Boix E. de-Las-Heras G. Domínguez-Muñoz E. Farré A. Fernández-Cruz L. Gómez L. Iglesias-García J. García-Malpartida K. Guarner L. Lariño-Noia J. Lluís F. López A. Molero X. Moreno-Pérez O. Navarro S. Palazón J. M. Pérez-Mateo M. Sabater L. Sastre Y. Vaquero E. C. Martínez J. (2013). The Spanish Pancreatic Club's recommendations for the diagnosis and treatment of chronic pancreatitis: Part 2 (treatment). Pancreatology 13 (1) 18–28.

  • Malesci A. Gaia E. Fioretta A. Bocchia P. Ciravegna G. Cantor P. Vantini I. (1995). No effect of long-term treatment with pancreatic extract on recurrent abdominal pain in patients with chronic pancreatitis. Scand. J. Gastroenterol. 30 (4) 392–398.

  • di Mola F. F. di Sebastiano P. (2008). Pain mechanisms in chronic pancreatitis. In: Beger H. G. Buchler M. Kozarek R. Lerch M. Neoptolemos J. Warshaw A. Whitcomb D. Shiratori K. (eds). The Pancreas: An Integrated Textbook of Basic Science Medicine and Surgery 2nd edn. (pp. 375–563). Oxford: Wiley-Blackwell.

  • Mössner J. Secknus R. Meyer J. Niederau C. Adler G. (1992). Treatment of pain with pancreatic extracts in chronic pancreatitis: Results of a prospective placebo-controlled multicenter trial. Digestion 53 (1–2) 54–66.

  • Mössner J. Stange J. Ewald M. Kestel W. Fischbach W. (1991). Influence of exogenous application of pancreatic extracts on endogenous pancreatic enzyme secretion. Pancreas6 (6) 637–44.

  • Mössner J. Wresky H. P. Kestel W. Zeeh J. Regner U. Fischbach W. (1989). Influence of treatment with pancreatic extracts on pancreatic enzyme secretion. Gut 30 (8) 1143–1149.

  • Novak I. Wang J. Henriksen K. Haanes K. A. Krabbe S. Nitschke R. Hede S. E. (2011). Pancreatic bicarbonate secretion involves two proton pumps. J. Biol. Chem. 286 (1) 280–9.

  • Orļikovs G. Pļaviņa I. Selezņovs J. Pokrotnieks J. Karpovs J. Voicehovska J. (2007). Pancreatic index: A new approach to chronic pancreatitis estimation. Proc. Latvian Acad. Sci. Section B 61 (1/2) 43–46.

  • Schneider A. Löhr J. M. Singer M. V. (2007). The M-ANNHEIM classification of chronic pancreatitis: Introduction of a unifying classification system based on a review of previous classifications of the disease. J. Gastroenterol. 42 (2) 101–119.

  • Slaff J. Jacobson D. Tillman C. Curington C. Toskes P. (1984). Protease-specific suppression of pancreatic exocrine secretion. Gastroenterology 87 44–52.

  • Song A. Bhagat L. Singh V. et al. (2002). Inhibition of cyclooxygenase-2 ameliorates the severity of pancreatitis and associated lung injury. Amer. J. Physiol. 283 G1166–G1174.

  • Trelle S. Reichenbach S. Wandel S. Hildebrand P. Tschannen B. Villiger P. M. Egger M. Jüni P. (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: Network meta-analysis. BMJ (British Medical Journal)342 c7086.

  • Warshaw A. Banks P. Fernández-Del Castillo C. (1998). AGA technical review: Treatment of pain in chronic pancreatitis. Gastroenterology 115 (3) 765–76.

  • Yadav D. Timmons L. Benson J. Dierkhising R. A. Chari S. T. (2011). Incidence prevalence and survival of chronic pancreatitis: A population-based study. Amer. J. Gastroenterol. 106 (12) 2192–2199.

Journal information
Impact Factor

CiteScore 2018: 0.3

SCImago Journal Rank (SJR) 2018: 0.137
Source Normalized Impact per Paper (SNIP) 2018: 0.192

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 237 106 2
PDF Downloads 130 79 3